Company news
Intellia Therapeutics, Inc. news in 2025
Intellia Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
November 9, 2025
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
November 7, 2025
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates
November 5, 2025
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
October 26, 2025
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
September 24, 2025
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
September 21, 2025
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema
September 17, 2025
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress
August 6, 2025
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
July 30, 2025
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
June 14, 2025
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
May 17, 2025
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress
May 7, 2025
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates
April 30, 2025
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy
April 2, 2025
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
March 25, 2025
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress
February 26, 2025
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates
February 19, 2025
Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
January 21, 2025
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
January 8, 2025
Calls in 2025
- Intellia Therapeutics (NASDAQ:NTLA) Q3 2025 Earnings Call
Nov 6, 2025
Transcript - Intellia Therapeutics (NASDAQ:NTLA) Q2 2025 Earnings Call
Aug 7, 2025
Transcript - Intellia Therapeutics (NASDAQ:NTLA) Q1 2025 Earnings Call
May 8, 2025
Transcript - Intellia Therapeutics (NASDAQ:NTLA) Q4 2024 Earnings Call
Feb 27, 2025
Transcript
Decks in 2025
- American Heart Association Scientific Sessions 2025 (AHA25)
Conference · 19 slides · November 2025
- Q2 2025 Earnings Presentation
Earnings · 33 slides · Aug 7, 2025